205 related articles for article (PubMed ID: 10449124)
1. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
Greene DA; Arezzo JC; Brown MB
Neurology; 1999 Aug; 53(3):580-91. PubMed ID: 10449124
[TBL] [Abstract][Full Text] [Related]
2. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
[TBL] [Abstract][Full Text] [Related]
3. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
[TBL] [Abstract][Full Text] [Related]
4. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
[TBL] [Abstract][Full Text] [Related]
5. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
6. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
[TBL] [Abstract][Full Text] [Related]
7. The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats.
Yamamoto T; Takakura S; Kawamura I; Seki J; Goto T
Life Sci; 2001 Feb; 68(12):1439-48. PubMed ID: 11388695
[TBL] [Abstract][Full Text] [Related]
8. Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.
Shimoshige Y; Minoura K; Matsuoka N; Takakura S; Mutoh S; Kamijo M
Brain Res; 2009 Jan; 1247():182-7. PubMed ID: 18992730
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Bril V; Buchanan RA
Diabetes Care; 2004 Oct; 27(10):2369-75. PubMed ID: 15451902
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Bril V; Buchanan RA
Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
[TBL] [Abstract][Full Text] [Related]
11. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
Kamijo M; Basso M; Cherian PV; Hohman TC; Sima AA
Diabetes Res Clin Pract; 1994 Sep; 25(2):117-29. PubMed ID: 7821191
[TBL] [Abstract][Full Text] [Related]
12. Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat.
Kihara M; Mitsui Y; Shioyama M; Hasegawa T; Takahashi M; Takakura S; Minoura K; Kawamura I
Neurosci Lett; 2001 Sep; 310(2-3):81-4. PubMed ID: 11585572
[TBL] [Abstract][Full Text] [Related]
13. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
Bril V; Hirose T; Tomioka S; Buchanan R;
Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
[TBL] [Abstract][Full Text] [Related]
14. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
Fagius J; Jameson S
J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
[TBL] [Abstract][Full Text] [Related]
15. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
[TBL] [Abstract][Full Text] [Related]
16. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
[TBL] [Abstract][Full Text] [Related]
18. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
[TBL] [Abstract][Full Text] [Related]
20. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population.
Brown MJ; Bird SJ; Watling S; Kaleta H; Hayes L; Eckert S; Foyt HL;
Diabetes Care; 2004 May; 27(5):1153-9. PubMed ID: 15111537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
